At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 56 enrolled
Drug / intervention
PEGPH20 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1B Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan-High Solid Tumors
In Brief
A Phase 1 clinical trial evaluating PEGPH20 and Pembrolizumab for NSCLC and Gastric Cancer. Completed, enrolled 56 participants across 28 sites.
Detailed Summary
This is a Phase 1b study evaluating a combination of PEGPH20 and pembrolizumab in hyaluronan-high (HA-high) participants with relapsed/refractory non-small cell lung cancer (NSCLC) and HA-high participants with relapsed/refractory gastric adenocarcinoma (GAC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNSCLC, Gastric Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartOct 2015
Primary CompletionMar 2019
TodayJul 2026
First PostedSep 30, 2015
Enrollment StartOct 22, 2015
Primary CompletionMar 26, 2019
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 10.8 years ago
Interventions
PEGPH20drug
PEGPH20 will be administered as an intravenous (IV) infusion as per the dose schedule specified in the arm description.
Pembrolizumabdrug
Pembrolizumab will be administered as an IV infusion as per the dose schedule specified in the arm description.